Alemtuzumab - CAS 216503-57-0
Catalog number: B0084-305393
Category: Inhibitor
Please be kindly noted products are not for therapeutic use. We do not sell to patients.
Molecular Formula:
C6468H10066N1732O2005S40
Molecular Weight:
145453.80
COA:
Inquire
Description:
Alemtuzumab is a humanized monoclonal antibody that is used as a drug for the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL), T-cell lymphoma as well as multiple sclerosis. It acts via binding to CD52 which exist on the surface of mature lymphocytes. Alemtuzumab was approved as a second-line therapy for CLL.
Brife Description:
CD52, CLL, CTCL, T-cell lymphoma, multiple sclerosis, second-line therapy for CLL
Sequence:
1 QVQLQESGPG LVRPSQTLSL TCTVSGFTFT DFYMNWVRQP PGRGLEWIGF
51 IRDKAKGYTT EYNPSVKGRV TMLVDTSKNQ FSLRLSSVTA ADTAVYYCAR
101 EGHTAAPFDY WGQGSLVTVS SASTKGPSVF PLAPSSKSTS GGTAALGCLV
151 KDYFPEPVTV SWNSGALTSG VHTFPAVLQS SGLYSLSSVV TVPSSSLGTQ
201 TYICNVNHKP SNTKVDKKVE PKSCDKTHTC PPCPAPELLG GPSVFLFPPK
251 PKDTLMISRT PEVTCVVVDV SHEDPEVKFN WYVDGVEVHN AKTKPREEQY
301 NSTYRVVSVL TVLHQDWLNG KEYKCKVSNK ALPAPIEKTI SKAKGQPREP
351 QVYTLPPSRD ELTKNQVSLT CLVKGFYPSD IAVEWESNGQ PENNYKTTPP
401 VLDSDGSFFL YSKLTVDKSR WQQGNVFSCS VMHEALHNHY TQKSLSLSPG
451 K
Purity:
95%
Synonyms:
Alemtuzumab (usan/inn); Campath (tn); D02802; MabCampath
MSDS:
Inquire
Application:
the treatment of chronic lymphocytic leukemia (CLL), cutaneous T-cell lymphoma (CTCL), T-cell lymphoma as well as multiple sclerosis
Shelf Life:
2 years
Quantity:
Data not available, please inquire.
1.Fulminant Central Nervous System Nocardiosis in a Patient Treated With Alemtuzumab For Relapsing-Remitting Multiple Sclerosis.
Penkert H1, Delbridge C2, Wantia N3, Wiestler B4, Korn T5. JAMA Neurol. 2016 Apr 4. doi: 10.1001/jamaneurol.2016.0146. [Epub ahead of print]
2.Molecular treatment effects of alemtuzumab in skeletal muscles of patients with IBM.
Schmidt K1, Kleinschnitz K2, Rakocevic G3, Dalakas MC3,4, Schmidt J5,6. BMC Neurol. 2016 Apr 16;16:48. doi: 10.1186/s12883-016-0568-5.
BACKGROUND: Mechanisms of inflammation and protein accumulation are crucial in inclusion body myositis (IBM). Recent evidence demonstrated that intravenous immunoglobulin failed to suppress cell-stress mediators in IBM. Here we studied the molecular changes in skeletal muscle biopsies from patients with IBM before and after treatment with alemtuzumab.
3.Alemtuzumab for multiple sclerosis.
Riera R1, Porfírio GJ, Torloni MR. Cochrane Database Syst Rev. 2016 Apr 15;4:CD011203. doi: 10.1002/14651858.CD011203.pub2.
BACKGROUND: Multiple sclerosis (MS) is an autoimmune, T-cell-dependent, inflammatory, demyelinating disease of the central nervous system, with an unpredictable course. Current MS therapies focus on treating exacerbations, preventing new exacerbations and avoiding the progression of disability. However, at present there is no effective treatment that is capable of safely and effectively reaching these objectives. This has led to the development and investigation of new drugs. Recent clinical trials suggest that alemtuzumab, a humanised monoclonal antibody against cell surface CD52, could be a promising option for MS.
4.Alemtuzumab and Multiple Sclerosis: Another Note of Caution.
Hohlfeld R1, Kümpfel T2. JAMA Neurol. 2016 Apr 4. doi: 10.1001/jamaneurol.2016.0259. [Epub ahead of print]
Molecular Weight Calculator Molarity Calculator Solution Dilution Calculator

Related Products


CAS 76684-89-4 Loxistatin Acid

Loxistatin Acid
(CAS: 76684-89-4)

Loxistatin Acid, a derivative of E-64, is an irreversible and membrane-permeant cysteine protease inhibitor.

CAS 104344-23-2 Bisoprolol fumarate

Bisoprolol fumarate
(CAS: 104344-23-2)

Bisoprolol is a beta-adrenoceptor blocking drug (beta-blocker). More specifically, it is a selective type β1 adrenergic receptor blocker.

CAS 1421373-62-7 Mutant EGFR inhibitor

Mutant EGFR inhibitor
(CAS: 1421373-62-7)

Mutant EGFR inhibitor is a potent and selective mutant EGFR inhibitor extracted from patent WO 2013014448 A1. It inhibits EGFRL858R, EGFRExon 19 deletionand EGF...

AL-3152
(CAS: 126048-33-7)

AL-3152 is a aldehyde reductase inhibitors originated by Alcon. But clinical trials was discontinued for the treatment of Diabetic nephropathies, Diabetic neuro...

TY-52156
(CAS: 934369-14-9)

TY-52156 is a potent and selective sphingosine-1-phosphate receptor 3 (SIP3) antagonist in a competitive manner with Ki value of 110 nM. It preferentially inhib...

CAS 144602-02-8 IRL-1038

IRL-1038
(CAS: 144602-02-8)

IRL-1038 is an ETB endothelin receptor antagonist. It inhibits ETB receptor-mediated contraction of tracheal smooth muscle and guinea-pig ileal without any sign...

CAS 10129-56-3 PETCM

PETCM
(CAS: 10129-56-3)

PETCM is an activator of caspase-3 and a stimulator of apoptosome formation in HeLa cell cytosols. It acts via inhibition of the oncoprotein ProT, therefore sti...

CAS 146062-49-9 MSDC-0160

MSDC-0160
(CAS: 146062-49-9)

MSDC-0160 reduces resistance in the insulin/IGF-1 signaling pathway and restores IGF-1-induced Akt and GSK-3 phosphorylation.

Quick Inquiry

Verification code

Featured Items